EMN39

About this trial

This study is testing whether a newer type of immunotherapy, called linvoseltamab, can help the body’s immune system find and destroy myeloma cells more effectively than the current standard treatment. Researchers also want to learn whether patients treated with linvoseltamab can achieve longer-lasting control of their cancer, while maintaining an acceptable safety profile and quality of life.

Patient Profile

This study is for adults who have been newly diagnosed with multiple myeloma and are not suitable candidates for a stem cell transplant, often because of their age, overall health, or other medical conditions. Participants must have active, measurable myeloma and be well enough to receive treatment, but must not have received previous therapy for their myeloma.

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, University Hospital Limerick, and University Hospital Galway

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	EMN39
Number:	25-31
Full Title:	A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Principal Investigator:	Dr. Janusz Krawczyk
Type:	Industry Sponsored
Sponsor:	Janssen
Recruitment Started:	Global: Dec 2025 Ireland: Jan 2026

Global Recruitment Target:	1000
Ireland Recruitment Target:	60